Sonoma Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Sonoma Pharmaceuticals (NASDAQ:SNOA) Second Quarter 2025 Results

Key Financial Results

• Revenue: US$3.58m (up 31% from 2Q 2024).
• Net loss: US$610.0k (loss narrowed by 59% from 2Q 2024).
• US$0.59 loss per share (improved from US$5.75 loss in 2Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sonoma Pharmaceuticals EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 8.3%. Earnings per share (EPS) exceeded analyst estimates by 34%.

Looking ahead, revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are up 13% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 4 warning signs for Sonoma Pharmaceuticals (3 are potentially serious!) that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.